Q4/2024 12/31/2024 EPS -4.670 ZacksConsensus -0.310 ActVsEst (4.360) - Miss
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide [Yahoo! Finance]Yahoo! Finance
- Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients WorldwideBusiness Wire
- Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 [Yahoo! Finance]Yahoo! Finance
- Exact Sciences (NASDAQ:EXAS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Halper Sadeh LLC Reminds Shareholders of EXAS, DVN, NFBK of the Firm’s InvestigationsGlobeNewswire
EXAS
Earnings
- 11/3/25 - Beat
EXAS
Sec Filings
- 1/30/26 - Form DEFA14A
- 1/23/26 - Form DEFA14A
- 1/9/26 - Form DEFM14A
- EXAS's page on the SEC website